We wished to examine potential associations among blood concentrations of fatty acid-binding protein (FABP) 4 and parameters in health check-ups such as abdominal fat area (AFA) and blood pressure (BP) in middle-aged Japanese males. We conducted a cross-sectional study of males who participated in health check-ups in Japan. We excluded participants diagnosed with metabolic diseases by the time of their check-up. A total of 305 subjects (30-64 [mean6standard deviation, 47.368.5] y) were recruited. Areas of totalabdominal, visceral and subcutaneous fat were measured using computed tomography. We compared the association of serum concentrations of FABP4 with various clinical parameters by Pearson product-moment correlation coefficient (PPMCC) analyses, and by stepwise multivariate linear regression analyses (MLRA). PPMCC analyses showed that blood concentrations of FABP4 were positively associated with: body mass index; areas of fat (total abdominal, visceral, subcutaneous); systolic BP; diastolic BP; total cholesterol; low-density lipoprotein-cholesterol; triacylglycerol; activities of g-glutamyl transpeptidase, aspartate aminotransferase and alanine aminotransferase; white blood cell count; and levels of creatinine.
J Nutr Sci Vitaminol, 61, [291] [292] [293] [294] [295] [296] [297] [298] 2015 Recent studies have shown that fatty acid-binding protein (FABP) 4 is present in adipocytes and macrophages, and is also a novel adipocytokine secreted from adipocytes into blood (1) . Animal studies have suggested that FABP4 is related to the development of insulin resistance and atherosclerosis (2) (3) (4) . It has been reported that injection of a chemical inhibitor of FABP4 into animals reduced the development of atherosclerosis (5) . Cross-sectional studies demonstrated blood concentrations of FABP4 to be positively associated with obesity, insulin resistance, hypertension and carotid atherosclerosis in: 234 South Korean adults; 806 American patients with type-2 diabetes mellitus (T2DM); and 459 Chinese patients who had undergone coronary angiography (6) (7) (8) . Furthermore, cohort studies demonstrated that blood concentrations of FABP4 in 495 non-T2DM subjects and 1,847 subjects without previous cardiovascular disease (CVD) in China were positively associated with subsequent metabolic syndrome (MetS) and carotid atherosclerosis (9, 10) . In addition, serum FABP4 concentrations were significant predictors for subsequent development of MetS in a 4-y follow-up for 465 subjects in South Korea (11) . In Japan, serum concentrations of FABP4 were reported to be positively correlated with the body mass index (BMI), blood pressure (BP), low-density lipoprotein-cholesterol (LDL-C) level, homeostasis model assessment as an index of insulin resistance (HOMA-IR) and mean left ventricular (LV) wall thickness, and negatively correlated with high-density lipoproteincholesterol (HDL-C) level, in a general population of 82 males and 108 females (12) . Positive associations between blood concentrations of FABP4 and BP were strong in these studies. However, several studies have demonstrated that obesity is a strong risk factor for BP elevation (13) . Whether a positive association between FABP4 concentrations and BP is independent of abdominal fat areas (AFAs) has not been investigated.
Blood concentrations of FABP4 were reported to be closely associated with LV diastolic dysfunction (which is related to BP dysfunction) in severely obese German subjects (14) . In Japan, blood concentrations of FABP4 were found to be positively associated with LV diastolic dysfunction in a general population of 190 subjects (male/female: 82/108), and this association disappeared when BMI was inserted in multiple linear regression analyses (MLRA) (12) . With respect to BP, it was reported that serum concentrations of FABP4 were higher in 30 Japanese subjects with essential hypertension than in 18 normotensive subjects, and that this association was independent of age, sex, and BMI (15) . However, whether blood concentrations of FABP4 are positively associated with BP in a continuous fashion from a healthy state to a hypertensive state in a larger general population is not known. AFAs (total area of abdominal fat, visceral fat, or subcutaneous fat) can also be assessed by computed tomography (CT) to examine independent associations between blood concentrations of FABP4 and BP from abdominal fat. A recent study demonstrated that serum concentrations of FABP were independently and positively associated with sarcopenic obesity as assessed by CT (16) . However, a potential association between blood concentrations of FABP4 and abdominal fat in a general population by CT has not been assessed. Furthermore, whether a positive association between blood concentrations of FABP4 and BP is independent from AFA as assessed by CT has not been studied.
We examined independent associations of blood FABP4 concentrations with AFAs (total abdominal fat, visceral fat, and subcutaneous fat), which was assessed by CT, or BP by MLRA in 305 middle-aged Japanese males who were not taking medications for metabolic diseases.
MATERIALS AND METHODS
Ethical approval of the study protocol. The study protocol was approved by the Ethics Committee of the University of Shizuoka (Shizuoka, Japan) based on the Declaration of Helsinki. All subjects provided written informed consent for use of their personal information.
Subjects. We conducted a cross-sectional study of 305 middle-aged Japanese males (30- We excluded subjects under treatment for: stroke; hypertension; cardiac disease; T2DM; hyperlipidemia; diseases of the liver, kidney, bladder or prostate gland; gout; psychiatric illness; cancer; ulcerative connectivetissue disease; adenoiditis; pancreatitis; rheumatism; accessory thyroid diseases; thyroid diseases; muscular atrophy; severe muscular asthenia; lung diseases (obstruction, emphysema, pneumonia, sarcoidosis, acute bronchitis, or interstitial lung disease); Behçet's disease; Graves' disease; Parkinsonian tremor; nephrosis syndrome; epilepsy; thrombocytopenia purpura; cholelithiasis; cholecystitis; cingulum; multiple myositis; distension of the common bile duct; systemic lupus erythematosus; hyperuricemia; pleurisy; and Hashimoto's thyroiditis.
Anthropometric data and blood samples were collected from each participant by trained medical staff. Smoking status was recorded as the number of cigarettes per day and duration of smoking (years). Self-reported physical activity was recorded as the number of exercise sessions undertaken each week (0-7). Dietary habits, energy intake, and alcohol intake during the previous month were assessed using a brief self-administered diet history questionnaire (BDHQ) (17, 18) . The BDHQ was a fourpage, structured document with three sections: general dietary behavior and major cooking methods; frequency of consumption of food/drink; intake of five alcoholic beverages. Food and beverage items and their standard portion sizes were derived from a previously developed self-administered diet history questionnaire (DHQ) (19) (20) (21) , a 16-page structured questionnaire comprising seven sections. Estimated dietary intake of 48 food and beverage items, energy, and 42 nutrients was calculated using an ad hoc computer algorithm developed for the BDHQ. This algorithm was based primarily on the Standard Tables of Food Composition in Japan set by the Science and Technology Agency in 2000.
Measurements. After an overnight fast, BP [diastolic blood pressure (DBP) and systolic blood pressure (SBP)], height and weight were measured; blood samples were collected from each subject. BMI was calculated as weight in kilograms divided by the square of height in meters. Serum samples were stored at 280˚C for subsequent assays.
Levels of total cholesterol (TC), HDL-C, LDL-C, triacylglycerol (TG), fasting plasma glucose, hemoglobin A1c (HbA1c), aspartate aminotransferase (AST), alanine aminotransferase (ALT), g-glutamyl-transpeptidase (GTP), creatinine, and high-sensitivity C-reactive protein (CRP; using the latex agglutination method) were measured, and the leukocyte count recorded. AFAs (total abdominal fat, visceral fat, and subcutaneous fat) were measured using CT.
Serum levels of FABP4 were measured using an enzyme-linked immunosorbent assay kit (Bio Vendor R&D, Mordrice, Czech Republic) with calibration and quality control undertaken according to manufacturer instructions.
Statistical analyses. Clinical and biochemical data are the mean6standard deviation (SD), median, minimum, and maximum. Pearson product-moment correlation coefficient (PPMCC) analyses were used to calculate the correlations for FABP4 and each parameter as continuous variables. Correlation between FABP4 and categorized data to tertiles was calculated by PPMCC analyses. Previous studies have demonstrated that MLRA is useful for the selection of independent variables in various parameters (22, 23) .
Step-wise MLRA was done to examine the independent association between the blood concentration of FABP4 and other parameters. Independent variables for the MLRA were selected using parameters with significant associations according to PPMCC analyses such as BMI, AFA (total abdominal, visceral, and subcutaneous fats), SBP, DBP, TC, HDL-C, TG, g-GTP,
AST, ALT, creatinine, and white blood cell count. CRP was included in the MLRA because association between FABP4 and categorized CRP was significant. To avoid multicollinearity in the MLRA, total abdominal fat area and LDL-C were excluded in the MLRA because these are strongly associated with subcutaneous fat and total cholesterol, respectively (R for PPMCC analyses was .0.8) and associations of total abdominal fat area and LDL-C with FABP4 concentrations were weaker than those of subcutaneous fat and total cholesterol, respectively. Inclusion criteria and exclusion criteria for step-wise MLRA were under p,0.02 and p$0.02, respectively. For all analyses, p,0.05 was considered significant. All statistical analyses were carried out using JMP v9.0 (SAS Institute Japan Co., Ltd., Tokyo, Japan).
RESULTS
Study subjects were all middle-aged Japanese males who were not taking medications for metabolic diseases. Characteristics of the subjects are shown in Table 1 . Five, 39, 21, 24 and two subjects had fasting glucose .125 mg/dL, HbA1c .6.0%, SBP .139 mmHg, DBP .89 mmHg, and TG .149 mg/dL, respectively.
PPMCC analyses for serum concentrations of FABP4 as continuous variable of each parameter showed that FABP4 concentrations were positively associated with: BMI; AFAs (total abdominal, visceral, and subcutaneous); SBP; DBP; TC; LDL-C; TG; activities of g-GTP, AST, and ALT; creatinine; white blood cell count; and levels of creatinine. p for the correlation between blood concentrations of FABP4 and categorized data to tertiles for each parameter was determined. Significant positive associations were observed for BMI, AFAs (total abdominal, visceral, and subcutaneous), SBP, DBP, g-GTP activity, AST activity, ALT activity, and white blood cell count as well as levels of creatinine, TC, LDL-C, TG and CRP. A significant negative association with HDL-C level was also noted (Table 2) .
Next, we carried out step-wise MLRA for FABP4 using parameters as independent variables with significant association by PPMCC analyses. Areas of fats (visceral and subcutaneous), SBP, DBP, HDL-C, TG, creatinine ALT, alanine transferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; g-GTP, g-glutamyl transpeptidase; FABP4, fatty acid binding protein 4; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TC, total cholesterol; TG, triglyceride; SBP, systolic blood pressure; SD, standard deviation. (Table 3) .
DISCUSSION
The present study focused on the associations among serum concentrations of FABP4, abdominal fat (measured by CT) and BP. We found a positive association between blood concentrations of FABP4 and indicators of abdominal fat, such as BMI and the area of fat (total abdominal, visceral, and subcutaneous). Studies have demonstrated that blood concentrations of FABP4 are positively associated with the prevalence of obesity, insulin resistance, T2DM and/or carotid atherosclerosis in Asian countries (6) (7) (8) 24) . Those studies, along with the present study, suggest that blood concentrations of FABP4 are positively associated with the prevalence of obesity in middle-aged Japanese males not taking medi- cations for metabolic diseases. We observed positive associations between serum concentrations of FABP4 and areas of fat (visceral and subcutaneous) ( Table 3 ). It is known that insulin resistance and abdominal fat areas are related to inflammation status, and that enlarged adipocytes express insulin-resistant adipokines such as tumor necrosis factor (TNF)-a and resistin (25) . It has been reported that blood concentrations of TNF-a are strongly positively associated with AFA (particularly visceral-fat area) (26) . Additionally, it has been reported that the blood concentration of CRP (an inflammation marker measured frequently in health check-ups) is positively associated with an indicator for overweight/obesity such as areas of visceral adipose tissue (27) . We observed a weak positive association between FABP4 and categorical data of CRP concentrations in blood (Table 2) . Thus, insulin resistance and inflammation status could be related to FABP4 concentration. Whether the blood concentration of FABP4 is associated with insulin-resistant adipokines such as TNF-a and resistin in this population should be studied.
Interestingly, we found that serum concentrations of FABP4 were positively associated with SBP and DBP in middle-aged Japanese males not taking medications for metabolic diseases. Associations between serum concentrations of FABP4 and AFAs (visceral and subcutaneous) or DBP remained in MLRA using parameters as independent variables with a significant association by PPMCC analyses (Table 3) . These results suggest that positive associations between blood concentrations of FABP4 and BP or parameters for abdominal fat are independent from other independent variables. FABP4 is expressed in adipocytes and macrophages (1). Thus, blood concentrations of FABP4 may indicate adiposity-and macrophage activation-associated development of hypertension and MetS-related diseases. Whether abdominal fats (subcutaneous fat and visceral fat), or macrophages contribute to blood concentrations of FABP4 should be investigated.
FABP4 was found to induce the development of insulin resistance and atherosclerosis in a model of atherosclerosis employing apolipoprotein-E deficient (ApoE 2/2 ) mice and mice with genetic disruption of FABP4 (28) . In addition, injection of a chemical inhibitor of FABP4 into ApoE 2/2 mice was found to inhibit the development of atherosclerosis (5). Thus, blood concentrations of FABP4 could be associated with subsequent hypertension-associated CVD. However, a causal association between blood concentrations of FABP4 and hypertension or subsequent development of CVD has not been demonstrated, and further studies are warranted.
Here, we observed that association between blood concentrations of FABP4 and DBP were stronger than with SBP (Tables 2 and 3 ). DBP has been reported to be a strong risk factor for the development of CVD in those aged ,50 y, whereas SBP is a strong risk factor in those aged .60 y (29) . Our recent study demonstrated that blood concentrations of soluble E-selectin (an adhesion molecule that induces attachment of leukocytes to blood vessels and a risk factor of CVD development) in the same study cohort as the present study were strongly positively associated with DBP rather than SBP (30) . Subjects in the present study had a mean age of 47.368.5 y. Thus, the stronger association of blood concentrations of FABP4 with DBP rather than with SBP in the present study could be because of the younger age of the participants and the earlier developmental stage of CVD. Whether there is an association between blood concentrations of FABP4 and DBP or SBP in elderly subjects warrants investigation. Furthermore, whether higher blood concentrations of FABP4 and/or soluble E-selectin in middle-aged Japanese males not taking medications for metabolic diseases leads to a higher prevalence of CVD should also be studied. In MLRA, we found a positive and independent association between serum concentrations of FABP4 and creatinine levels among parameters tested in this population (Table 3 ). Blood concentrations of FABP4 were reported to be positively associated with renal dysfunction in T2DM patients without microalbuminuria (161 T2DM patients and 102 healthy non-T2DM controls) (31) . Thus, higher blood concentrations of FABP4 in the general population and in subjects with T2DM may be associated with higher risks of development of nephropathy.
We showed an association between the blood concentration of FABP4 and areas of abdominal fats (visceral and subcutaneous), and between the blood concentration of FABP4 and DBP by MLRA. However, R 2 for the MLR analyses was relatively low (adjusted R 2 50.456) ( Table 3) . R 2 value of MLRA denotes the relevance of the multiple regression equation. Hence, it is difficult to predict the blood concentration of FABP4 by predictor variables using this equation, and other factors (including blood parameters and lifestyle factors) would also be related to the circulating concentration of FABP4. The reason why R 2 for the MLRA is relatively low could be that our study population was healthy subjects and subjects with low-grade metabolic disorders. Additionally, FABP4 expressed in the blood of the healthy individuals was relatively high. Thus, factors such as hormones and growth factors secreted steadily in the body would be related to maintenance of the blood concentration of FABP4. In addition, it is possible to make an association between the blood concentration of FABP4 and insulinresistant adipokines such as TNF-a and resistin. Thus, our results suggest that the association between the blood concentration of FABP4 and areas of abdominal fats (visceral and subcutaneous) and between the blood concentration of FABP4 and DBP are independent from other parameters in health check-ups determined in this study. However, other factors out of the parameters used in the present study could be related to the blood concentration of FABP4. Thus, other putative factors potentially related to the blood concentration of FABP4 should be identified. The association between the blood concentration of FABP4 and abdominal fat areas (total abdominal, visceral and subcutaneous), and between FABP4 and DBP by MLRAs with such putative factors should also also be examined.
The cross-sectional design of the present study could not be used to identify the causal relationship among blood concentrations of FABP4, AFAs, and BP. In particular, whether FABP4 is a risk factor for the development of hypertension and/or CVD because blood levels of FABP4 are positively strongly associated with abdominal fat was not investigated. Additionally, the study cohort was relatively small. An independent association between blood levels of FABP4 and BP from AFAs was not tested in other regions in the general population or in subjects with hypertension or other metabolic diseases. Therefore, the association between blood concentrations of FABP4, hypertension, AFAs or subsequent elevation of BP and prevalence of CVD should be investigated in longitudinal studies in many regions of different countries.
In conclusion, we showed that blood concentrations of FABP4 are positively and independently associated with BP and AFAs (visceral and subcutaneous) in middle-aged Japanese males not taking medications for metabolic diseases.
